HCW Biologics (HCWB) has upcoming FDA regulatory milestones for HCW11-018b. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by HCW Biologics (HCWB).
Over the past two years, HCW Biologics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
HCW11-018b, HCW9302, and HCW9206. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
HCW11-018b FDA Regulatory Timeline and Events
HCW11-018b is a drug developed by HCW Biologics for the following indication: Treat Solid Tumors.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- HCW11-018b
- Announced Date:
- October 9, 2026
- Target Action Date:
- H1 2027
- Estimated Target Date Range:
- January 1, 2027 - June 30, 2027
- Indication:
- Treat Solid Tumors
Announcement
HCW Biologics Inc announced that the IND application remains on track to be filed in 1H 2027
Read Announcement- Drug:
- HCW11-018b
- Announced Date:
- October 9, 2026
- Indication:
- Treat Solid Tumors
Announcement
HCW Biologics Inc. a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, maintains momentum toward filing an IND application to evaluate HCW11-018b, the lead product candidate in its second-generation, non-Fc-based T-Cell Engager Program, in the treatment of solid tumors.
Read Announcement- Drug:
- HCW11-018b
- Announced Date:
- July 23, 2026
- Indication:
- Treat Solid Tumors
Announcement
HCW Biologics Inc announced that it has requested a Type B (pre-IND application) meeting with the U.S. FDA to discuss the development and regulatory strategy for its investigational lead product candidate, HCW11-018b, a tetravalent T-cell engager ("TCE") constructed with the Company’s proprietary TRBC drug development platform.
AI Summary
HCW Biologics Inc. said it has requested a Type B pre-IND meeting with the U.S. FDA to discuss the development and regulatory plan for HCW11-018b, its lead investigational tetravalent T-cell engager. The company says the drug candidate is built using its proprietary TRBC platform and is designed to target solid tumors that overexpress human tissue factor.
HCW11-018b has shown potential in cancers such as gynecologic and pancreatic tumors. HCW Biologics also said it has created a streamlined manufacturing process to produce high-quality cGMP material at a lower cost than current methods, which could support future development and supply needs.
Read Announcement
HCW9302 FDA Regulatory Timeline and Events
HCW9302 is a drug developed by HCW Biologics for the following indication: For alopecia areata.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- HCW9302
- Announced Date:
- June 16, 2026
- Indication:
- For alopecia areata
Announcement
HCW Biologics Inc announced a positive preliminary human data readout for the first two dose cohorts from its dose-escalating Phase 1 clinical trial of HCW9302, an IL-2 based fusion immunotherapeutic, in patients with alopecia areata.
AI Summary
HCW Biologics said early human data from the first two dose groups in its Phase 1 trial of HCW9302, an IL-2 based fusion immunotherapy, looked positive in people with alopecia areata. In the second dose group, all participants who received 3 micrograms per kilogram had a clinical response after a single dose. The company said the treatment was well tolerated, with no dose-limiting toxicities or major side effects linked to IL-2 therapy. No cases of capillary leak, cytokine release syndrome, or higher blood eosinophil counts were reported.
The trial is still moving through dose escalation, and the company has started treating patients in the third dose group. HCW Biologics said it aims to identify a recommended Phase 2 dose by the end of 2026.
Read Announcement- Drug:
- HCW9302
- Announced Date:
- June 16, 2026
- Indication:
- For alopecia areata
Announcement
HCW Biologics Inc. announced a positive preliminary human data readout for the first two dose cohorts from its dose-escalating Phase 1 clinical trial of HCW9302, an IL-2 based fusion immunotherapeutic, in patients with alopecia areata.
AI Summary
HCW Biologics Inc. reported encouraging early results from the first two dose groups in its Phase 1 trial of HCW9302, an IL-2 based fusion immunotherapeutic for alopecia areata. The company said the treatment was designed to expand and activate regulatory T cells, which may help control autoimmune disease.
In the second dose group, all participants receiving 3 micrograms per kilogram showed a positive clinical response after a single dose. HCW Biologics also said the drug was well tolerated, with no dose-limiting toxicities or major IL-2-related side effects. No cases of capillary leak syndrome, cytokine release syndrome, or increased blood eosinophil counts were reported. The company said it is continuing dose escalation and expects to identify the recommended Phase 2 dose by the end of 2026.
Read Announcement- Drug:
- HCW9302
- Announced Date:
- November 18, 2025
- Indication:
- For alopecia areata
Announcement
HCW Biologics Inc announced the first patient was dosed at The Ohio State University Wexner Medical Center for the Company-sponsored, multi-center first-in-human clinical trial to evaluate HCW9302 in patients with alopecia areata (NCT07049328).
AI Summary
HCW Biologics announced the first patient has been dosed at The Ohio State University Wexner Medical Center in its company‑sponsored, multi‑center, first‑in‑human trial of HCW9302 for alopecia areata (NCT07049328). This Phase 1, dose‑escalation study plans to treat up to 30 patients and will assess safety, tolerability, and the recommended dose to move into Phase 2. Secondary goals include measuring disease responses and effects on immune cells, especially regulatory T (Treg) cells.
HCW9302 is a subcutaneous, first‑of‑its‑kind interleukin‑2 (IL‑2) fusion molecule designed to activate and expand Treg cells to reduce harmful inflammation without broad immune activation. The company believes HCW9302 could suppress the autoimmune attack on hair follicles that causes alopecia areata and may be studied later for other autoimmune and inflammatory skin conditions if Phase 1 results support further development.
Read Announcement- Drug:
- HCW9302
- Announced Date:
- June 27, 2025
- Indication:
- For alopecia areata
Announcement
HCW Biologics Inc. announced that its scientists have successfully developed second-generation, multi-specific T-cell engagers against solid tumors, particularly for pancreatic cancer, using its novel proprietary TRBC product discovery and development platform technology.
AI Summary
HCW Biologics Inc. scientists have successfully developed second-generation, multi-specific T‑cell engagers to fight solid tumors, with a special focus on pancreatic cancer. Using their novel, proprietary TRBC product discovery and development platform, these engineered molecules not only target cancer-specific antigens and activate T cells through CD3 engagement but also work to reduce immunosuppression in the tumor environment. This dual action enhances the ability of T cells to infiltrate and attack the tumor, offering a promising new approach in treating aggressive cancers.
The breakthrough is significant since innovative approaches are needed for challenging cancers like pancreatic cancer, where treatment options remain limited. Early preclinical studies have shown potent, antigen-specific anti-cancer activity at safe dose levels, suggesting that these T‑cell engagers could pave the way for broader immunotherapy applications in solid tumors and improve outcomes for patients in need.
Read Announcement- Drug:
- HCW9302
- Announced Date:
- February 3, 2025
- Indication:
- For alopecia areata
Announcement
HCW Biologics Inc announced that it has received clearance of its Investigational New Drug Application ("IND") from the U.S. Food and Drug Administration ("FDA") to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments.
AI Summary
HCW Biologics Inc. announced that it has received FDA clearance for its Investigational New Drug Application (IND) to start a first-in-human Phase 1 dose escalation clinical trial. The trial will evaluate HCW9302, a new drug candidate, in patients with moderate-to-severe alopecia areata—a common autoimmune condition that currently lacks a curative treatment approved by the FDA. Alopecia areata causes sudden hair loss and greatly impacts quality of life, making effective treatment options highly needed.
HCW9302 is an innovative, injectable interleukin-2 fusion protein designed to activate and expand regulatory T cells that help reduce unwanted immune responses. The trial aims to determine the safe dosage that effectively enhances Treg cell activity, potentially offering a transformative treatment not only for alopecia areata but also paving the way for therapy development in other autoimmune diseases.
Read Announcement
HCW9206 FDA Regulatory Events
HCW9206 is a drug developed by HCW Biologics for the following indication: for immunotherapy with increased function.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- HCW9206
- Announced Date:
- March 16, 2026
- Indication:
- for immunotherapy with increased function
Announcement
HCW Biologics Inc. announced today results of groundbreaking research studies, published in the peer-reviewed, high-impact journal, Science Advances (Cole et al., "IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR-T cells enriched in long-lived T memory stem cells" Science Advances, 13 Mar 2026, Vol 12, Issue 11).
AI Summary
HCW Biologics Inc. announced results from groundbreaking research published in Science Advances (Cole et al., "IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR-T cells enriched in long-lived T memory stem cells," Science Advances, 13 Mar 2026, Vol 12, Issue 11). The paper describes HCW9206, a commercialization-ready cytokine-fusion scaffold that programs human CAR-T cells to be more functional and to contain more long-lived T memory stem cells, which are linked to durable immune responses.
In experimental models, CAR-T cells manufactured with HCW9206 showed strong anti-tumor activity against leukemia and improved antiviral potency against HIV, suggesting potential for curative outcomes. Using HCW9206 as a manufacturing reagent may simplify production and lower the cost of CAR-T therapies, potentially making these treatments more accessible and supporting further development for cancer and infectious disease applications.
Read Announcement- Drug:
- HCW9206
- Announced Date:
- May 13, 2025
- Indication:
- for immunotherapy with increased function
Announcement
HCW Biologics Inc. nnounced today presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor - T cells (CAR-Ts) for immunotherapy with increased function.
AI Summary
HCW Biologics Inc. recently presented studies showing that its proprietary fusion protein, HCW9206, offers a new pathway to generate enhanced chimeric T-cell receptor (CAR-T) cells for immunotherapy. The protein works by delivering combined signals from three different immune‐stimulatory cytokines in one molecule, showing superior performance over standard methods that use anti-CD3/anti-CD28 and IL-2 for viral transduction and expansion of CAR-T cells.
The studies highlighted that HCW9206 not only improves the efficiency of CAR-T cell production but also boosts the generation of stem cell-like memory T cells (Tscm), known for their lasting in vivo persistence and potent cell-killing ability. This breakthrough method promises to lower manufacturing costs and enhance the functional activities and longevity of CAR-T therapies, potentially improving treatments for cancers and other chronic diseases.
Read Announcement
Free HCWB Stock Alerts